Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 4
2005 2
2009 2
2010 3
2011 5
2012 5
2013 4
2014 3
2015 3
2016 7
2017 7
2018 5
2019 4
2020 6
2021 2
2022 5
2023 3
2024 2
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP; ORION-10 and ORION-11 Investigators. Ray KK, et al. Among authors: kallend d. N Engl J Med. 2020 Apr 16;382(16):1507-1519. doi: 10.1056/NEJMoa1912387. Epub 2020 Mar 18. N Engl J Med. 2020. PMID: 32187462 Free article. Clinical Trial.
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, Wijngaard PLJ, Curcio D, Jaros MJ, Leiter LA, Kastelein JJP; ORION-9 Investigators. Raal FJ, et al. Among authors: kallend d. N Engl J Med. 2020 Apr 16;382(16):1520-1530. doi: 10.1056/NEJMoa1913805. Epub 2020 Mar 18. N Engl J Med. 2020. PMID: 32197277 Free article. Clinical Trial.
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.
Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, Wijngaard P, Horton JD, Taubel J, Brooks A, Fernando C, Kauffman RS, Kallend D, Vaishnaw A, Simon A. Fitzgerald K, et al. Among authors: kallend d. N Engl J Med. 2017 Jan 5;376(1):41-51. doi: 10.1056/NEJMoa1609243. Epub 2016 Nov 13. N Engl J Med. 2017. PMID: 27959715 Free PMC article. Clinical Trial.
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials.
Ray KK, Raal FJ, Kallend DG, Jaros MJ, Koenig W, Leiter LA, Landmesser U, Schwartz GG, Lawrence D, Friedman A, Garcia Conde L, Wright RS; ORION Phase III investigators. Ray KK, et al. Among authors: kallend dg. Eur Heart J. 2023 Jan 7;44(2):129-138. doi: 10.1093/eurheartj/ehac594. Eur Heart J. 2023. PMID: 36331326 Free PMC article.
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, Leiter LA, Landmesser U, Schwartz GG, Friedman A, Wijngaard PLJ, Garcia Conde L, Kastelein JJP; ORION Phase III Investigators. Wright RS, et al. Among authors: kallend dg. J Am Coll Cardiol. 2021 Mar 9;77(9):1182-1193. doi: 10.1016/j.jacc.2020.12.058. J Am Coll Cardiol. 2021. PMID: 33663735 Free article.
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, Hall T, Troquay RP, Turner T, Visseren FL, Wijngaard P, Wright RS, Kastelein JJ. Ray KK, et al. Among authors: kallend d. N Engl J Med. 2017 Apr 13;376(15):1430-1440. doi: 10.1056/NEJMoa1615758. Epub 2017 Mar 17. N Engl J Med. 2017. PMID: 28306389 Free article. Clinical Trial.
Effect of inclisiran on lipids in primary prevention: the ORION-11 trial.
Ray KK, Kallend D, Leiter LA, Raal FJ, Koenig W, Jaros MJ, Schwartz GG, Landmesser U, Garcia Conde L, Wright RS; ORION-11 Investigators. Ray KK, et al. Among authors: kallend d. Eur Heart J. 2022 Dec 21;43(48):5047-5057. doi: 10.1093/eurheartj/ehac615. Eur Heart J. 2022. PMID: 36331315 Free PMC article. Clinical Trial.
65 results